alosetron has been researched along with ondansetron in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Beer, CM; Bliss, BI; Chen, J; Christensen, KL; Cioffi, C; Cohen, ML; DeOrazio, RJ; Dobritsa, S; Fairfax, DJ; Fitzpatrick, K; Harding, JP; Hassler, C; Isaacson, S; Isherwood, M; Khmelnitsky, YL; Lynch, M; Maeng, JH; Manning, DD; Masih, L; Peterson, LH; Rennells, WM; Richards, JJ; Rust, T; Usyatinsky, A; Wierschke, JD; Yang, Z | 1 |
| Barnes, NM; Brady, CA; Butler, AS; Choo, SH; Cioffi, CL; Cohen, ML; Dobritsa, S; Earley, WG; Fitzpatrick, K; Guo, C; Guzzo, PR; Hassler, C; Manning, DD; Masih, L; Naginskaya, J; Ryan, KN; Sikkander, MI; Usyatinsky, A; Wierschke, JD; Zhang, Z | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Naylor, RJ; Rudd, JA | 1 |
| Barrett, VJ; Bountra, C; Butler, A; Cambridge, D; Clayton, NM; Gale, J; Humphrey, PP; Hunt, AA; Maxwell, MP; Sargent, R | 1 |
| Bush, TG; Sanders, KM; Smith, TK; Spencer, NJ; Watters, N | 1 |
| Bayliss, MK; Harris, AJ; Houston, JB; Somers, GI | 1 |
| Bayliss, MK; Houston, JB; Somers, GI | 1 |
| Capria, E; Collins, S; Dodhia, VR; Fantuzzi, A; Gilardi, G; Huq, E; Mak, LH; Sadeghi, SJ; Somers, G | 1 |
1 review(s) available for alosetron and ondansetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for alosetron and ondansetron
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.
Topics: Benzoxazoles; Drug Discovery; Receptors, Serotonin, 5-HT3; Serotonin Antagonists | 2010 |
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
Topics: Animals; Cell Line; Disease Models, Animal; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Mice; Microsomes, Liver; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Agonists | 2011 |
Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret.
Topics: Animals; Carbolines; Cisplatin; Disease Models, Animal; Emetics; Ferrets; Ondansetron; Serotonin Antagonists | 1994 |
The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat.
Topics: Adrenergic alpha-Agonists; Animals; Carbolines; Clonidine; Drug Evaluation, Preclinical; Fasting; Gastrointestinal Transit; Intestine, Small; Ondansetron; Ovalbumin; Radioligand Assay; Rats; Reference Values; Reflex; Serotonin Antagonists; Vagus Nerve | 1999 |
Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
Topics: Animals; Carbolines; Colon; Colonic Diseases, Functional; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents; Humans; Ileum; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Myoelectric Complex, Migrating; Ondansetron; Serotonin Antagonists; Sex Characteristics | 2001 |
The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.
Topics: Animals; Carbolines; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Hepatocytes; Humans; Kinetics; Male; Mass Spectrometry; Microsomes, Liver; Ondansetron; Rats; Rats, Wistar; Recombinant Proteins; Serotonin Antagonists | 2007 |
The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human.
Topics: Animals; Carbolines; Clinical Laboratory Techniques; Dogs; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Microsomes, Liver; Ondansetron; Rats; Rats, Wistar; Serotonin Antagonists; Species Specificity; Substrate Specificity | 2007 |
An electrochemical microfluidic platform for human P450 drug metabolism profiling.
Topics: Carbolines; Cytochrome P-450 Enzyme System; Electrochemical Techniques; Electrodes; Humans; Microfluidics; Microsomes, Liver; Nifedipine; Ondansetron; Quinidine; Substrate Specificity | 2010 |